Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

As with other drugs, Darzalex Faspro (daratumumab/hyaluronidase-fihj) can cause side effects, such as upper respiratory tract infection. If you’re not able to ...

Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...

The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is entrenched in multiple myeloma care for several ...

The company's flagship product, Darzalex, has been a major revenue driver, but the company is now working to diversify its portfolio and prepare for the post-Darzalex era. Want deeper insights ...

Darzalex & Darzalex Faspro are indicated for the treatment of multiple myeloma. Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

Most products closed the year strong with Darzalex royalties leading the way. Epkinly net sales were $78 million, and this was slightly lower than expected due to one-time adjustments in France ...

Its key product, Darzalex, is responsible for a majority of its revenue. Recent strategic actions include leveraging partnerships and investing heavily in research and development to expand its ...

Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s JNJ Darzalex and Roche’s Phesgo. The company’s top line comprises ...